Australia Pharmaceuticals Market Analysis - Industry Growth, Size & Forecast Report (2025 - 2030)

The Analysis of Pharmaceutical Industry in Australia is Segmented by ATC/Therapeutic Class (Alimentary Tract and Metabolism, Blood and Blood Forming Organs, Cardiovascular System, Dermatologicals, Genito Urinary System and Sex Hormones, Systemic Hormonal Preparations, Anti-Infectives for Systemic Use, Antineoplastic and Immunomodulating Agents, Musculoskeletal System, Nervous System, Antiparasitic Products, Insecticides, and Repellents, Respiratory System, Sensory Organs, and Other Therapeutic Classes), Drug Type (Branded and Generic), and Prescription Type (Prescription Drugs (Rx) and OTC Drugs). The Report Offers the Value (in USD Million) for the Above Segments.

Australia Pharmaceuticals Market Analysis - Industry Growth, Size & Forecast Report (2025 - 2030)

Australia Pharmaceutical Market Size

Australia Pharmaceuticals Market
Study Period 2019 - 2030
Base Year For Estimation 2024
Forecast Data Period 2025 - 2030
Market Size (2025) USD 14.04 Billion
Market Size (2030) USD 19.01 Billion
CAGR (2025 - 2030) 6.25 %
Market Concentration Medium

Major Players

Australia Pharmaceuticals Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Australia Pharmaceuticals Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Australia Pharmaceutical Market Analysis

The Australia Pharmaceuticals Market size is estimated at USD 14.04 billion in 2025, and is expected to reach USD 19.01 billion by 2030, at a CAGR of 6.25% during the forecast period (2025-2030).

The COVID-19 pandemic had a significant impact on the Pharmaceutical Industry in Australia. Many companies received approval for their vaccines against the SARS-CoV-2 virus and focused their Pharmaceutical Research and development on therapeutics against COVID-19. For instance, in January 2021, the Therapeutic Goods Administration approved the COVID-19 vaccine developed by Pfizer and BioNTech, enhancing Pfizer's Market Share in the country. In addition, the Australian government signed nearly four agreements and invested around AUD 3.3 billion to support the supply of vaccines in the country. Furthermore, the country invested around AUD 363 million in research and development activities related to the prevention and treatment of COVID-19. Such developments accelerated market growth during the pandemic. Furthermore, the Australian Government convened a large group of clinical experts to form the National COVID-19 Clinical Evidence Taskforce. The role of the Taskforce is to create evidence-based Australian guidelines for the clinical care of people with COVID-19. The Therapeutic Goods Administration (TGA) approved Tixa Genmab and Ciljevima (Evoshield) in December 2021 and Sotrovimab (Xevudy) in August 2021 for COVID-19 treatment. Hence, it is observed that the COVID-19 pandemic had a significant impact on the market studied.

The major factors likely to drive market growth during the forecast period are the growing burden of chronic diseases and the rising geriatric population, along with rising investments in research and development expenditure for novel therapeutics in Australia. According to the Australian Bureau of Statistics data updated in March 2022, over three-quarters, i.e., 78.6% of Australians, had at least one long-term health condition in 2021, while nearly half, 46.6% or 11.6 million, had at least one chronic condition. Thus, increasing chronic diseases and a high demand for Pharmaceutical Products are expected to promote market growth. Furthermore, the burden of diabetes has also increased in the country. As per data from the International Diabetes Federation's 2021 report, there were about 1.5 million people with diabetes in Australia in 2021, and their number is expected to increase to 1.9 million by 2045. Thus, the demand for pharmaceuticals for diabetes treatment and management is expected to increase over the years in Australia, which is expected to boost growth in the Pharmaceuticals Industry in the country, contributing to the Pharmaceutical Market Trends.

Additionally, key strategies adopted by major market players, increased investment, and rising Pharmaceutical Research and development activities will also contribute to market growth. For instance, in June 2022, diabetes-focused biotech player Dimerix entered into a partnership agreement with the Australian Centre for Accelerating Diabetes Innovations (ACADI) to conduct a clinical trial of its oral medical product DMX-200 in diabetic kidney disease patients. Positive results from such studies will boost their demand, hence boosting the Pharmaceutical Manufacturing process and thereby driving the market during the study period. Thus, the above-mentioned factors are expected to positively contribute to the Growth in the Pharmaceutical Industry over the study period.

However, strict regulatory guidelines for product approvals are expected to hinder market growth.

Australia Pharmaceutical Industry Overview

The Australian Pharmaceutical Market is highly competitive and consists of several major players. In terms of market share, a few of the major players are currently dominating the market. Some prominent players are vigorously making acquisitions and joint ventures with other companies to consolidate their market positions in the country. Some of the Top Pharmaceutical Companies in Australia currently dominating the market are AbbVie Inc., Amgen Inc., Pfizer Inc., AstraZeneca, and Eli Lilly and Company.

Australia Pharmaceutical Market Leaders

  1. Abbvie Inc.

  2. Amgen Inc.

  3. AstraZeneca plc

  4. Eli Lilly & Co.

  5. Pfizer Inc.

  6. *Disclaimer: Major Players sorted in no particular order
Australia Pharmaceuticals Market  Concentration
Need More Details on Market Players and Competiters?
Download PDF

Australia Pharmaceutical Market News

  • Jun, 2022: Tetra Bio-Pharma launched its new wholly owned subsidiary 'Tetra Bio-Pharma Australia' (TBP-AU), an Australian-based research company focused on the execution of clinical trials in Australia.
  • Mar, 2022: Antengene Corporation Limited announced that the Therapeutic Goods Administration (TGA) of the Australian Government Department of Health has registered XPOVIO (selinexor) for the treatment of adult patients with multiple myeloma (MM).

Australia Pharmaceutical Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Geriatric Population and Increasing Investments in the Sector
    • 4.2.2 Rising Incidence of Chronic Diseases such as CVD and Diabetes
  • 4.3 Market Restraints
    • 4.3.1 Stringent Regulatory Scenario
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products and/ or Services
    • 4.4.5 Degree of Competition/Intensity of Competitive Rivalry

5. MARKET SEGMENTATION (Market Size by Value - in USD Million)

  • 5.1 By ATC/Therapeutic Class
    • 5.1.1 Alimentary Tract and Metabolism
    • 5.1.2 Blood and Blood Forming Organs
    • 5.1.3 Cardiovascular System
    • 5.1.4 Dermatologicals
    • 5.1.5 Genito Urinary System and Sex Hormones
    • 5.1.6 Systemic Hormonal Preparations
    • 5.1.7 Anti-infectives for Systemic Use
    • 5.1.8 Antineoplastic and Immunomodulating Agents
    • 5.1.9 Musculoskeletal System
    • 5.1.10 Nervous System
    • 5.1.11 Antiparasitic Products, Insecticides, and Repellents
    • 5.1.12 Respiratory System
    • 5.1.13 Sensory Organs
    • 5.1.14 Other Therapeutic Classes
  • 5.2 By Drug Type
    • 5.2.1 Branded
    • 5.2.2 Generic
  • 5.3 By Prescription Type
    • 5.3.1 Prescription Drugs (Rx)
    • 5.3.2 OTC Drugs

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 AbbVie Inc.
    • 6.1.2 AstraZeneca PLC
    • 6.1.3 Amgen Inc.
    • 6.1.4 Pfizer Inc.
    • 6.1.5 CSL Limited
    • 6.1.6 F. Hoffmann-La Roche AG
    • 6.1.7 GlaxoSmithKline PLC
    • 6.1.8 Eli Lilly and Company
    • 6.1.9 Novartis AG
    • 6.1.10 Sanofi SA
    • 6.1.11 Johnson and Johnson
    • 6.1.12 Merck KGaA
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Australia Pharmaceutical Industry Segmentation

As per the scope of this report, pharmaceuticals are referred to as prescription and non-prescription drugs. These medicines can be bought by an individual with or without the doctor's prescription and are safe for consumption for various illnesses with or without the doctor's consent. The Australia Pharmaceuticals Market is segmented by ATC/Therapeutic Class (Alimentary Tract and Metabolism, Blood and Blood Forming Organs, Cardiovascular System, Dermatologicals, Genito Urinary System and Sex Hormones, Systemic Hormonal Preparations, Anti-infectives for Systemic Use, Antineoplastic and Immunomodulating Agents, Musculoskeletal System, Nervous System, Antiparasitic Products, Insecticides, and Repellents, Respiratory System, Sensory Organs, and Other Therapeutic Classes), Drug Type (Branded and Generic), and Prescription Type (Prescription Drugs (Rx) and OTC Drugs). The report offers the value (in USD million) for the above segments.

By ATC/Therapeutic Class Alimentary Tract and Metabolism
Blood and Blood Forming Organs
Cardiovascular System
Dermatologicals
Genito Urinary System and Sex Hormones
Systemic Hormonal Preparations
Anti-infectives for Systemic Use
Antineoplastic and Immunomodulating Agents
Musculoskeletal System
Nervous System
Antiparasitic Products, Insecticides, and Repellents
Respiratory System
Sensory Organs
Other Therapeutic Classes
By Drug Type Branded
Generic
By Prescription Type Prescription Drugs (Rx)
OTC Drugs
Need A Different Region or Segment?
Customize Now

Australia Pharmaceutical Market Research FAQs

How big is the Australia Pharmaceuticals Market?

The Australia Pharmaceuticals Market size is expected to reach USD 14.04 billion in 2025 and grow at a CAGR of 6.25% to reach USD 19.01 billion by 2030.

What is the current Australia Pharmaceuticals Market size?

In 2025, the Australia Pharmaceuticals Market size is expected to reach USD 14.04 billion.

Who are the key players in Australia Pharmaceuticals Market?

Abbvie Inc., Amgen Inc., AstraZeneca plc, Eli Lilly & Co. and Pfizer Inc. are the major companies operating in the Australia Pharmaceuticals Market.

What years does this Australia Pharmaceuticals Market cover, and what was the market size in 2024?

In 2024, the Australia Pharmaceuticals Market size was estimated at USD 13.16 billion. The report covers the Australia Pharmaceuticals Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Australia Pharmaceuticals Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Australia Pharmaceutical Industry Report

The pharmaceutical industry in Australia is poised for sustained growth, driven by an aging population and the increasing prevalence of chronic diseases like diabetes. This industry trend is boosting demand for ongoing treatment management. The market is primarily dominated by the prescription drugs segment, benefiting from substantial investments in research and development for innovative therapeutics. Additionally, there is a notable surge in the adoption of generic drugs, spurred by government initiatives and their cost-effectiveness.

Technological advancements in medical technology and the introduction of efficient drug monitoring systems are enhancing prescription safety and further fueling market expansion. Strategic partnerships and an emphasis on expanding drug portfolios are expected to continue driving the positive trajectory of the pharmaceutical industry in Australia. For a detailed market forecast and analysis, refer to the latest industry reports which offer insights into market share, size, and revenue growth trends. Access a free report PDF download for an in-depth industry analysis.

The growth rate of the industry is significant, with market research indicating a promising future. The industry analysis reveals critical industry information, including the industry outlook and the industry size. Industry statistics highlight the industry trends, with market data supporting these findings. The market forecast predicts continued market growth, with market leaders playing a pivotal role in shaping the market outlook.

A comprehensive market overview provides a clear understanding of market predictions and market review. Market segmentation further clarifies the market value, offering a detailed report example. The report pdf is essential for research companies looking to delve deeper into the industry.

Industry research is crucial for understanding industry sales and market trends. The industry profile and industry report provide valuable insights into the sector analysis, industry revenue, and industry worth. The market analysis and market structure are key components of understanding the industry's dynamics. The market cap and sales data further illustrate the market's financial aspects.

The annual report and industry data offer a comprehensive view of the market's performance, while the market report and market overview provide a snapshot of current trends. The market outlook and industry forecast give a glimpse into the future, with market leaders and market statistics offering a detailed analysis. The research analysis and largest companies are highlighted in the report, providing a thorough understanding of the industry's landscape.